Taiwanese dBio will set up its European HQ and AI center in Luxembourg, tapping into the country’s data economy and strategic location for healthtech scale-up.
Decentralized Biotechnology Intelligence Group (dBio), a leading Taiwanese healthtech innovator, is expanding into Europe with the set up of its new headquarters and AI research center in Luxembourg. At a press event held at TeroHouse17, the company showcased the platform through a live demonstration and premiere of its official launch video.
The company’s flagship solution, GMOT Cloud, integrates AI-powered insoles and lightweight wearables capable of delivering real-time movement and biometric data with clinical-grade precision.
“Luxembourg is one of the best-connected countries in Europe, with all compounds connected to high-speed internet.”
The technology’s application spans professional sports, rehabilitation, and continuous heart monitoring — with future extensions into medical-grade tracking and animal health.
“The biggest opportunity for dBio is to bridge that gap, all the way from fitness to wellness and a better, longer, healthier life.” said Hubertus ‘Bert’ Hoyt, dBio’s newly appointed Board Advisor. Hoyt, a veteran executive from Puma and Nike, will support dBio’s European strategy.
Luxembourg as a key launchpad for European expansion
The decision to base operations in Luxembourg is a strategic one. Mario Grotz, CEO of Luxinnovation, outlined the country’s strong positioning for healthtech ventures. “Luxembourg is one of the best-connected countries in Europe, with all compounds connected to high-speed internet,” he said. He also pointed to the government’s long-standing investment in AI, data security, and digital infrastructure as key enablers for dBio’s growth.
Grotz highlighted dBio first collaboration with Lunex University, and promised continued support through Luxinnovation, helping dBio connect with relevant research centers and funding instruments for R&D activities. With Luxembourg’s multilingual talent pool and proximity to major markets like Germany and France, the country offers a launchpad for European-scale operations.
Luxembourg has selected “four to five” sectors as part of its official AI strategy, including the health sector, said Grotz.
David Chou, Chairman of dBio, signed the partnership agreement with Hoyt during the ceremony, reinforcing the company’s commitment to long-term development in the region.
The company currently employs around 25 people in Taiwan. With more than 75 patents filed globally and in-house development of both hardware and software, dBio is positioning itself at the forefront of personalized health technology. The firm is currently exploring additional partnerships in both public health and elite sport, with Hoyt suggesting more strategic announcements may follow in Q3 2025.
dBio’s expansion arrives at a moment when both investors and policymakers are looking closely at the intersection of AI and healthcare. With European regulations tightening around data use and wearable devices edging toward clinical-grade territory, Luxembourg could provide dBio with both regulatory clarity and market access.
